Thymosin Alpha-1 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of Thymosin Alpha-1 is not established. This means dosing twice weekly is typical to maintain stable levels. The half-life directly affects how long Thymosin Alpha-1 remains active and influences optimal injection timing.
What Is the Half-Life of Thymosin Alpha-1?
The half-life of Thymosin Alpha-1 is not established. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer Thymosin Alpha-1 to maintain therapeutic blood levels.
What Does Thymosin Alpha-1's Half-Life Mean for Dosing?
With a half-life of not established, Thymosin Alpha-1 requires dosing twice weekly to maintain stable levels. The standard dosage of 1.6-6.4 mg per dose via subcutaneous injection accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, Thymosin Alpha-1 reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For Thymosin Alpha-1, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject Thymosin Alpha-1?
Optimal timing depends on your research goals. A half-life of not established means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (twice weekly) for more stable levels throughout the day.
How Does Thymosin Alpha-1's Half-Life Compare to Similar Peptides?
Thymosin Alpha-1 is a Thymic peptide, immunomodulator. Its half-life of not established positions it with a longer duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your Thymosin Alpha-1 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Thymosin Alpha-1.
Open Calculator →Bottom Line: Thymosin Alpha-1 Half-Life and Dosing
Thymosin Alpha-1 has a half-life of not established, supporting the standard protocol of 1.6-6.4 mg per dose dosed twice weekly over 5-7 day injection cycles, repeated as needed.
Read our Thymosin Alpha-1 dosage guide for complete protocol details.
Complete Guide
Thymosin Alpha-1 : Benefits, Dosage, Side Effects & Research
Related Reading
- Thymosin Alpha-1 Dosage Guide
- Thymosin Alpha-1 Benefits
- Thymosin Alpha-1 Side Effects
- Thymosin Alpha-1 Stacking Guide
- Thymosin Alpha-1 Cycle Guide
- Thymosin Alpha-1 Research
Research-Grade Sourcing
If you're going to research Thymosin Alpha-1, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Thymosin alpha 1 (28-amino acid peptide)) is a Thymic peptide, immunomodulator. Naturally occurring peptide isolated from thymus gland; synthetic form (thymalfasin/Zadaxin) developed for immune enhancement. It is researched for immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant.
What is the recommended Thymosin Alpha-1 dosage?
Common dosages: 1.6-6.4 mg per dose administered twice weekly via subcutaneous injection. Cycle length: 5-7 day injection cycles, repeated as needed. Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of Thymosin Alpha-1?
Well-tolerated. Local injection site reactions most common. Safe in liver disease, cancer, and autoimmune conditions. No significant organ toxicity.
Is Thymosin Alpha-1 safe?
Thymosin Alpha-1 has shown a favorable safety profile in research. FDA-approved (Zadaxin) for specific cancer and hepatitis indications. Prescription medication. All research should follow appropriate safety protocols.